江浩-—安徽—肺癌脑转移的治疗.ppt

一石激起千重浪？ Mulvenna P,et al. Lancet.?2016 Oct 22;388(10055):2004-2014. WBRT for NSCLC：Yes No？ 本研究的一般描述 a non-inferiority, phase 3 randomised trial done at 69 UK and three Australian centres. NSCLC patients with brain metastases unsuitable for surgical resection or stereotactic radiotherapy optimal supportive care (OSC) including dexamethasone plus WBRT (20 Gy in five daily fractions) or OSC alone including dexamethasone The primary outcome measure：quality-adjusted life-years (QALYs). QALYs were generated from overall survival and patients’ weekly completion of the EQ-5D questionnaire. Between